According to the industry's 2017 pharmaceutical market report, the global prescription drug market will grow steadily with a compound growth rate of 6.5% in the next five years, reaching US$1.06 trillion in 2022, among which biological products will grow steadily and will occupy the pharmaceutical market in 2022. % share, up to $326 billion. At present, China's biomedical industry is experiencing explosive growth, with a compound annual growth rate of 16%. The industry expects to continue to grow in the future, with huge development potential, mainly affected by three major aspects: policy, technological innovation and capital.
In recent years, China's biomedical industry has been promising. On January 12, 2017, the National Development and Reform Commission officially issued the “13th Five-Year Plan for Biological Industry Development”, proposing that by 2020, the scale of the bio-industry will reach 8-10 trillion yuan. on May 10 this year, the Ministry of Science and Technology formulated and issued The "13th Five-Year Plan for Biotechnology Innovation" will clarify the special targets for biotechnology innovation in the "13th Five-Year Plan" and accelerate the development of biomedical innovation in China.
In addition, the launch of “Healthy China 2030” and “Several Policies to Promote the Development of Biomedical Industry” have created a good environment for biomedical innovation in China and provided a favorable development platform for biopharmaceutical enterprises.
Leading by technological innovation.
In recent years, with the gradual improvement of the biotechnology industry platform and supporting industrial facilities, and the support of relevant policies, the research and development strength of China's biomedical industry enterprises has also been continuously enhanced, and a number of technologies have emerged on the world stage. . For example, in the field of stem cell research, China has also leapt to the forefront of the world, and individual directions are in a "leading" position.
In addition, as the domestic biomedical industry is improving, the demand for talent is also expanding. According to industry data, there are more than 1 million people in China's biomedical research and development, of which 30% have returned from overseas in recent years. The accumulation of these talents will promote the further innovation and upgrading of China's biomedical industry.
Capital flows into the market
According to authoritative data, the size of China's biomedical market in 2017 was about 145.8 billion yuan, which has become an important driving force for the growth of the global pharmaceutical market. In this context, huge market potential will inevitably lead to the pursuit of capital.
In addition, with the acceleration of large-scale business restructuring of the pharmaceutical industry and the pulling of business integration requirements, it will inevitably bring more impetus to future biopharmaceutical M&A transactions.
The industry said that through diversified capital operation methods such as investment and mergers and asset restructuring, it will further enhance the concentration of pharmaceutical industry and commerce, promote the rise of innovative drugs, high-end medical devices, Internet medical and other emerging areas, and promote the optimization and upgrading of industrial structure.